pharma · Chronic Obstructive Pulmonary Disease (COPD) · Non-Small Cell Lung Cancer
AstraZeneca
AstraZeneca AB
AstraZeneca is a pharma organization headquartered in cambridge, GB. Primary therapeutic focus areas include Chronic Obstructive Pulmonary Disease (COPD), Non-Small Cell Lung Cancer, Asthma, Advanced Solid Tumors, Not ap
Company details
- Status
- Public
- HQ
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
- Employees
- 79,242
- Programs
- 249
- Drugs
- 238
- Patents
- 2
D910DC00001
Phase 3 · small molecule · Histologically or cytologically confirmed Locoregional Hepatocellular Carcinoma (HCC) and successfully completed curative therapy (resection or ablation)
D910DC00001 for Histologically or cytologically confirmed Locoregional Hepatocellular Carcinoma (HCC) and successfully completed curative therapy (resection or ablation) is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Internal code D910DC00001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- AstraZeneca AB
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Histologically or cytologically confirmed Locoregional Hepatocellular Carcinoma (HCC) and successfully completed curative therapy (resection or ablation)
- Status
- active
- Trials
- 1